Search clinical trials for: Cirmtuzumab plus ibrutinib

Total 5148 results

National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

United States
M.D. Anderson Cancer Center

Completed

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, Spain, Belgium, Germany, Russian Federation
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma | Refractory Follicular...

United States
Dana-Farber Cancer Institute
Pharmacyclics LLC.

Completed

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Waldenstrom's Macroglobulinemia

United States
X4 Pharmaceuticals

Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Waldenstrom's Macroglobulinemia

United States, Greece
M.D. Anderson Cancer Center
Pharmacyclics LLC.

Active, not recruiting

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | Small Lymphocytic Leukemia

United States
Sunnybrook Health Sciences Centre
Novartis

Unknown

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Leukemia, Lymphocytic, Chronic, B-Cell

Canada
Gilead Sciences
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis

Hepatitis C | HIV | Liver Fibrosis | HIV/HCV Co-infection

United States
University of California, San Diego

Recruiting

Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
TG Therapeutics, Inc.

Completed

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (GENUINE)

Chronic Lymphocytic Leukemia

United States, Israel
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
Johnson & Johnson Private Limited

Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Pharmacyclics LLC.

Terminated

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States
Dartmouth-Hitchcock Medical Center

Completed

A Study of BNC105P Combined With Ibrutinib

Chronic Lymphocytic Leukemia

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic Lymphoma Group

Active, not recruiting

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

CLL

Netherlands, Denmark
M.D. Anderson Cancer Center
Amgen; Pharmacyclics LLC.

Terminated

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Lymphoma

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
French Innovative Leukemia Organisation
Janssen, LP

Active, not recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

Relapsed or Refractory Chronic Lymphocytic Leukemia

France
Barbara Parker, MD
Oncternal Therapeutics, Inc

Completed

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

Breast Neoplasms

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction (COUPLE)

Sexual Dysfunction | Erectile Dysfunction

France, Poland, United States, Belgium, Mexico, Malaysia, Canada, Taiwan, Korea, Republic of, Russian Federation, Argentina, Australia, United Kingdom
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
Gilead Sciences

Completed

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer

United States, Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Pharmacyclics LLC.

Completed

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
Pharmacyclics LLC.

Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Graft Versus Host Disease

United States
Icahn School of Medicine at Mount Sinai
Pharmacyclics LLC.

Terminated

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

High Risk Smoldering Multiple Myeloma

United States
University Hospital, Caen

Not yet recruiting

Is Ibrutinib-related Atrial Fibrillation Dose Dependent

Atrial Fibrillation | Hematological Malignancy

France
Novartis Pharmaceuticals

Terminated

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Chronic Lymphocytic Leukemia (CLL)

United States
Peter MacCallum Cancer Centre, Australia
Novartis

Active, not recruiting

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Mantle Cell Lymphoma Recurrent

Australia
Dana-Farber Cancer Institute
Eli Lilly and Company

Withdrawn

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute

Completed

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma

United States, Belgium, France, Germany, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Healthy Participants

Belgium
Incyte Corporation

Completed

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lymphoma

United States
German CLL Study Group
Janssen-Cilag Ltd.

Completed

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (CLL12)

Chronic Lymphocytic Leukemia

Germany
University of Michigan Rogel Cancer Center

Withdrawn

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Prof. Dr. Clemens Schmitt
Charite University, Berlin, Germany; Janssen-Cilag Ltd.

Active, not recruiting

Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 (ImbruVeRCHOP)

Diffuse Large B Cell Lymphoma

Germany
Nantes University Hospital
Roche Pharma AG; Janssen, LP

Active, not recruiting

A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients (OAsIs)

Mantle Cell Lymphoma

France, United Kingdom
Lahey Clinic

Completed

Lid Margin And Conjunctival Microbial Flora Following Punctum Occlusion

Dry Eye Syndrome

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

Leukemia, Lymphoblastic, Chronic

Italy
M.D. Anderson Cancer Center
Pharmacyclics LLC.

Terminated

Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

Lymphoma

United States
Pharmacyclics LLC.

Completed

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Diffuse Large Cell B-lymphoma

United States
Rabin Medical Center
Janssen, LP

Recruiting

Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

Central Nervous System Lymphoma

Israel
National Cancer Centre, Singapore
Samsung Medical Center; Singapore General Hospital

Terminated

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Lymphoma, B-Cell, Marginal Zone

Singapore
Eugene Nikitin

Unknown

Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia (ISRAEL)

AIHA - Warm Autoimmune Hemolytic Anemia

Russian Federation
Jason Robert Gotlib
National Cancer Institute (NCI)

Terminated

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Systemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic Mastocytosis

United States
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (Captivate)

Leukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Italy, New Zealand, Poland, Spain
Pharmacyclics LLC.

Active, not recruiting

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Follicular Lymphoma

United Kingdom, Portugal, Taiwan, Spain, Belgium, Netherlands, Israel, United States, Czechia, Italy, France, Hungary, Australia, Poland, Canada, Austria, Russian Federation, Greece, Turkey
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

Chronic Lymphocytic Leukemia

China
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Mantle Cell Lymphoma

United States, France, United Kingdom, Belgium, Spain, Israel, Puerto Rico, Poland, Russian Federation

Search clinical trials for: Cirmtuzumab plus ibrutinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations